Alteration of circulating Placental Leucine Aminopeptidase (P-LAP) activity in preeclampsia. 2010

Ruth Landau, and Alexandra Laverrière, and Paul Bischof, and Olivier Irion, and Michel Morales, and Marie Cohen
Department of Anesthesiology, University of Washington Medical Center, Seattle, WA , USA.

OBJECTIVE Placental Leucine Aminopeptiadse (P-LAP) also known as oxytocinase, is secreted by syncytiotrophoblast and increases gradually during pregnancy until delivery. It is a regulator of uterine contractions, of vascular resistance and of volume of the retroplacental blood pool. Recently, it was shown that it could also regulate metalloproteinase 9 activity and thus, invasiveness of trophoblastic cells. Since development of preeclampsia could be initiated by decreased cytotrophoblastic invasion of spiral arterioles and a reduced uteroplacental perfusion, we speculate that circulating P-LAP activity could be decreased during preeclampsia. METHODS Case-control study was evaluated in 84 women. P-LAP activity was measured in n=51 healthy pregnant women at term, and compared with n=16 normotensive women delivering preterm and n=17 women diagnosed with pre-eclampsia. P-LAP activity was determined by colorimetry in plasma samples using L-Leucine-p-nitroanilide as substrate. RESULTS P-LAP activity was significantly lower in sera of preeclamptic women (0.91+/-0.122 mDO/min) as compared to normotensive controls (1.41+/-0.103 mDO/min; p=0.003) irrespective of time of delivery. CONCLUSIONS These findings confirm the probable involvement of P-LAP in trophoblast invasion and development of preeclampsia.

UI MeSH Term Description Entries
D010122 Cystinyl Aminopeptidase A zinc-containing sialoglycoprotein that is used to study aminopeptidase activity in the pathogenesis of hypertension. EC 3.4.11.3. Cystine Arylamidase,Cystyl Aminopeptidase,Oxytocinase,Cystidyl Aminopeptidase,Cystinaminopeptidase,Cystine Aminopeptidase,Vasopressinase
D011225 Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease. Toxemias, Pregnancy,EPH Complex,EPH Gestosis,EPH Toxemias,Edema-Proteinuria-Hypertension Gestosis,Gestosis, EPH,Hypertension-Edema-Proteinuria Gestosis,Preeclampsia,Preeclampsia Eclampsia 1,Pregnancy Toxemias,Proteinuria-Edema-Hypertension Gestosis,Toxemia Of Pregnancy,1, Preeclampsia Eclampsia,1s, Preeclampsia Eclampsia,EPH Toxemia,Eclampsia 1, Preeclampsia,Eclampsia 1s, Preeclampsia,Edema Proteinuria Hypertension Gestosis,Gestosis, Edema-Proteinuria-Hypertension,Gestosis, Hypertension-Edema-Proteinuria,Gestosis, Proteinuria-Edema-Hypertension,Hypertension Edema Proteinuria Gestosis,Of Pregnancies, Toxemia,Of Pregnancy, Toxemia,Pre Eclampsia,Preeclampsia Eclampsia 1s,Pregnancies, Toxemia Of,Pregnancy Toxemia,Pregnancy, Toxemia Of,Proteinuria Edema Hypertension Gestosis,Toxemia Of Pregnancies,Toxemia, EPH,Toxemia, Pregnancy,Toxemias, EPH
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005260 Female Females
D005865 Gestational Age The age of the conceptus, beginning from the time of FERTILIZATION. In clinical obstetrics, the gestational age is often estimated from the onset of the last MENSTRUATION which is about 2 weeks before OVULATION and fertilization. It is also estimated to begin from fertilization, estrus, coitus, or artificial insemination. Embryologic Age,Fetal Maturity, Chronologic,Chronologic Fetal Maturity,Fetal Age,Maturity, Chronologic Fetal,Age, Embryologic,Age, Fetal,Age, Gestational,Ages, Embryologic,Ages, Fetal,Ages, Gestational,Embryologic Ages,Fetal Ages,Gestational Ages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

Ruth Landau, and Alexandra Laverrière, and Paul Bischof, and Olivier Irion, and Michel Morales, and Marie Cohen
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
Ruth Landau, and Alexandra Laverrière, and Paul Bischof, and Olivier Irion, and Michel Morales, and Marie Cohen
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
Ruth Landau, and Alexandra Laverrière, and Paul Bischof, and Olivier Irion, and Michel Morales, and Marie Cohen
December 1984, Nihon Sanka Fujinka Gakkai zasshi,
Ruth Landau, and Alexandra Laverrière, and Paul Bischof, and Olivier Irion, and Michel Morales, and Marie Cohen
July 1982, Experientia,
Ruth Landau, and Alexandra Laverrière, and Paul Bischof, and Olivier Irion, and Michel Morales, and Marie Cohen
July 1987, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
Ruth Landau, and Alexandra Laverrière, and Paul Bischof, and Olivier Irion, and Michel Morales, and Marie Cohen
June 2001, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
Ruth Landau, and Alexandra Laverrière, and Paul Bischof, and Olivier Irion, and Michel Morales, and Marie Cohen
April 1982, Nihon Sanka Fujinka Gakkai zasshi,
Ruth Landau, and Alexandra Laverrière, and Paul Bischof, and Olivier Irion, and Michel Morales, and Marie Cohen
January 1985, Archives of gynecology,
Ruth Landau, and Alexandra Laverrière, and Paul Bischof, and Olivier Irion, and Michel Morales, and Marie Cohen
April 1983, Nihon Sanka Fujinka Gakkai zasshi,
Ruth Landau, and Alexandra Laverrière, and Paul Bischof, and Olivier Irion, and Michel Morales, and Marie Cohen
February 1995, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!